A Phase 2 interventional study of OTX-DP (Dexamethasone punctum plug) and Placebo Vehicle Punctum Plug in Ocular Inflammation and Pain, sponsored by Ocular Therapeutix, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.
Among the 2,886 studies in Pain with a site in United States, this one is the 1,333rd largest by enrollment of the 2,564 interventional ones that give a count, is one of 139 that started in 2012, is one of 342 in phase 2, and was the 1,024th registered.
10,076 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 21–65
Yale University · Sites in United States
Ages 30–75
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 6–17
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,886 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 417 · Phase 3 375 · Phase 4 372
First in 1957; this study’s year is marked. 139 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 66 across the 2,564 interventional studies, 99 across the 299 observational. Of the 2,228 that completed or were terminated, 1,051 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
671 of 2,886 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Pain — fewer than ten, so there is no comparison to draw.
172 of the studies in Pain with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000281Phase 3Major Extremity Trauma Research ConsortiumEffect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures | 2026-11-30 |
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT07276542Phase 3The Ketamine Research FoundationClinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. | 2026-12-31 |
Add all 172 to your calendar (.ics) → With an account.
Among the 2,886 studies in Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
Drug: OTX-DP (Dexamethasone punctum plug)
Placebo punctum plug insertion
Drug: Placebo Vehicle Punctum Plug
Sustained and tapered release of dexamethasone from hydrogel punctum plug
Hydrogel punctum plug without dexamethasone
Absence of Cells in Anterior Chamber of Study Eye
Time frame: Day 8
Absence of Pain in the Study Eye
Time frame: Day 8
Adverse Events
Measure of adverse events over the duration of each subject's participation in the study.
Time frame: Duration of each individual subject's participation in the study, up to 60 days
| Milestone | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| Started | 30 | 30 |
| Completed | 28 | 29 |
| Not completed | 2 | 1 |
| Participants | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| Absence of Cells in Anterior Chamber of Study Eye | 6 | 3 |
| Participants | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| Absence of Pain in the Study Eye | 23 | 9 |
Measure of adverse events over the duration of each subject's participation in the study.
| Participants | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| Adverse Events | 4 | 7 |
Collected over The analyses of safety were based primarily on the incidence of treatment-emergent adverse events up to 60 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexamethasone Punctum Plug | — | 0/29 (0%) | 3/29 (10.3%) |
| Placebo Vehicle Punctum Plug | — | 1/30 (3.3%) | 10/30 (33.3%) |
| Event | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| SyncopeGeneral disorders | 0/29 | 1/30 |
| Event | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug |
|---|---|---|
| Eye disordersEye disorders | 3/29 | 10/30 |
| Age, Customized(Participants) | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug | Total |
|---|---|---|---|
| Age between 21 - 65 | 14 | 9 | 23 |
| Age greater than or equal to 65 | 16 | 21 | 37 |
| Sex: Female, Male(Participants) | Dexamethasone Punctum Plug | Placebo Vehicle Punctum Plug | Total |
|---|---|---|---|
| Female | 17 | 12 | 29 |
| Male | 13 | 18 | 31 |
Ran from Oct 2012 to primary completion in Aug 2013, 10 months.
Results were first posted in Apr 2017, 3 years 8 months after primary completion.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 10 months is above that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.